Whittier Trust Co. of Nevada Inc. lifted its holdings in Bristol-Myers Squibb (NYSE:BMY) by 5.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 130,529 shares of the biopharmaceutical company’s stock after purchasing an additional 7,214 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Bristol-Myers Squibb were worth $7,998,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in the stock. Delphi Private Advisors LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $108,000. Atlantic Trust LLC acquired a new position in Bristol-Myers Squibb during the 2nd quarter worth approximately $111,000. Massey Quick Simon & CO. LLC grew its holdings in Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 1,492 shares in the last quarter. Horan Capital Advisors LLC. acquired a new position in Bristol-Myers Squibb during the 3rd quarter worth approximately $122,000. Finally, Acrospire Investment Management LLC grew its holdings in Bristol-Myers Squibb by 633.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,200 shares of the biopharmaceutical company’s stock worth $123,000 after acquiring an additional 1,900 shares in the last quarter. Hedge funds and other institutional investors own 71.51% of the company’s stock.
Several research analysts have commented on BMY shares. Citigroup set a $78.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Friday, February 16th. Argus reiterated a “buy” rating and set a $66.43 price target (down previously from $75.00) on shares of Bristol-Myers Squibb in a report on Wednesday, March 21st. TheStreet cut shares of Bristol-Myers Squibb from a “b” rating to a “c+” rating in a report on Thursday, March 8th. Credit Suisse Group set a $62.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, January 22nd. Finally, Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Friday, January 19th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $66.68.
BMY stock traded down $1.43 on Friday, hitting $60.88. The company’s stock had a trading volume of 6,462,049 shares, compared to its average volume of 5,604,834. Bristol-Myers Squibb has a 1 year low of $51.56 and a 1 year high of $70.05. The company has a market cap of $101,726.25, a price-to-earnings ratio of 20.23, a price-to-earnings-growth ratio of 1.62 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The firm had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. Bristol-Myers Squibb’s revenue for the quarter was up 3.9% on a year-over-year basis. analysts anticipate that Bristol-Myers Squibb will post 3.22 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be given a $0.40 dividend. The ex-dividend date of this dividend is Thursday, April 5th. This represents a $1.60 annualized dividend and a yield of 2.63%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 53.16%.
COPYRIGHT VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/07/bristol-myers-squibb-co-bmy-shares-bought-by-whittier-trust-co-of-nevada-inc.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.